Companies
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
European Countries Criticised By PhRMA Report
May 2007 | Industry NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
US drug industry association PhRMA has included a number of European countries in its latest 'Special 301 Submission'. The report identifies specific countries that PhRMA feels should be placed on the United States Trade Representatives (USTR)'s Special 301 list regarding intellectual property (IP) violation and market access barriers. In 2007, PhRMA has singled out the European Union (EU) as a whole for criticism due to its policies of price restrictions and the rampant parallel trade in medicines that exists in its borders. However, on a positive note PhRMA recommends that Germany be downgraded from 'Priority Country' to the less severe